in recipients of allogeneic bone marrow or blood stem cell transplants. Allogeneic bone marrow transplantation for advanced hematologic cancer is associated with a high risk of early treatment-related morbidity and mortality. To determine the short-term benefits of allogeneic blood Materials and methods stem cell transplants when compared to bone marrow transplants, we reviewed outcomes of 74 adults with Patients advanced hematologic cancer transplanted from HLAmatched related donors after conditioning with thioFrom March 1992 to March 1995, 74 adults with advanced tepa, busulfan and cyclophosphamide. There were three hematologic cancer and HLA-matched related donors cohorts: group 1 received bone marrow transplants received allogeneic transplants after conditioning with with cyclosporine (CsA) and methotrexate (MTX) for high-dose thiotepa, busulfan and cyclophosphamide. Eligi-GVHD prophylaxis; group 2 received bone marrow bility criteria are described. 4 Patient characteristics are transplants with CsA and methylprednisolone (MP); listed in Table 1 . There were 36 males and 38 females. and group 3 received blood stem cells with CsA and MP.
/l were 28 (14-100؉), 19 (13-100؉)
undergone autologous marrow transplantation previously. and 14 (9-86) days post-transplant for groups 1, 2 and Data were analyzed for three cohorts of patients treated 3, respectively (P Ͻ 0.05 only for group 1 vs group 3 on two prospective studies (Table 1) . Group 1 received for both outcomes). Blood stem cell recipients had the bone marrow transplants with cyclosporine (CsA) and least regimen-related toxicity, fewest early deaths and methotrexate (MTX) as GVHD prophylaxis; group 2 earliest discharge. There was no significant difference received bone marrow transplants with CsA and methylin acute GVHD between the three groups. One hundred prednisolone (MP) as GVHD prophylaxis; and group 3 and eighty-day survivals (95% CI) were 53% (35-72%), received blood stem cell transplants with CsA and MP as 32% (10-53%), and 68% (49-87%) for groups 1, 2 and GVHD prophylaxis. The groups did not differ significantly 3, respectively (P Ͻ 0.05 only for group 2 vs group 3).
with regard to any of the pretreatment characteristics (Table For allogeneic transplantation, use of blood stem cell 1). All protocols were approved by the Institutional Review grafts has substantial advantages over marrow grafts.
Board of the MD Anderson Cancer Center, and written Keywords: allogeneic blood stem cell transplant; leukeinformed consent was obtained from each participant. mia; treatment-related mortality Marrow and blood stem cell collection prophylactic ganciclovir from engraftment to day 100. The discharge criteria were the same for all three groups; for Donors were HLA-matched and related. Blood stem cells discharge, the patients had to be ambulatory, afebrile, tolerwere collected from filgrastim-treated donors by apheresis ating oral medications, eating 1000 kcal daily, and drinking as described.
1,5 Apheresis was continued until a minimum 1 l of fluid daily. of 4 ϫ 10 6 CD34 ϩ cells/kg recipient body weight were collected.
GVHD prophylaxis and treatment

Supportive care
CsA was administered at 3 mg/kg/day i.v. continuous infusion from day Ϫ2, and doses were adjusted to maintain Filgrastim 5 g/kg/day subcutaneously was given from day whole blood steady state or trough levels at 250-350 ng/ml 7 for 10 patients in group 1 and from day 1 for the remainby RIA for parent drug. Eighteen patients in group 1 ing 64 patients. Groups 1 and 2 received filgrastim until received MTX at 10 mg/m 2 i.v. on days 1, 3 and 6, and the the neutrophil count exceeded 1.5 ϫ 10 9 /l for 3 days, and other 12 patients received MTX at 15 mg/m 2 i.v. on day 1, group 3 received filgrastim until the day the neutrophil and 10 mg/m 2 i.v. on days 3, 6 and 11. The patients in count exceeded 1.0 ϫ 10 9 /l. All blood products were group 2 received MP at 0.5 mg/kg/day beginning on day 7 irradiated and filtered. Patients were given 2 units of red with an increase to 1.0 mg/kg/day on day 15 and a taper blood cells for hemoglobin Ͻ80 g/l and 4 units of platelets thereafter. 4 The patients in group 3 received MP at (or one single-donor pack equivalent to 6 units) for platelet 1.0 mg/kg/day beginning day 5 with a taper thereafter.
1 count Ͻ20 ϫ 10 9 /l. Infection prophylaxis during the periPatients who developed grade 2 GVHD were treated transplant period consisted of nonabsorbable antibiotics initially with MP at 0.5 mg/kg i.v. q 6 h. Antithymocyte orally, vancomycin 1 g intravenously daily, fluconazole globulin 10 mg/kg/day i.v. was given to some patients with 200 mg intravenously every 12 h, and acyclovir 5 mg/kg gastrointestinal involvement at the onset of GVHD and to intravenously every 8 h. All patients received broad specpatients with steroid-refractory GVHD (unresponsive to trum antibiotics for neutropenic fever and hyperaliment-MP at 2 mg/kg/day ϫ 3). ation when needed.
Intravenous immunoglobulin 200-500 mg/kg was given weekly to day 100 and monthly thereafter to 1 year. Once Toxicity grading engrafted, the patients also received twice-weekly trimethoprim-sulfamethoxazole orally or pentamidine by inhalation Regimen-related toxicity (RRT) was graded as described 6 except that deaths after day 28 resulting from RRT occurevery 3 weeks, and CMV-seropositive patients received 457 Table 2 Hematopoietic recovery and support Between-group comparisons of demographic data, regimenrelated toxicity, and development of steroid-resistant GVHD were made by 2 analysis or log-likelihood ratio. Actuarial estimates of time to engraftment, discharge, GVHD, and death were calculated according to the method of Kaplan and Meier. Comparisons of time to event were made using the Peto and Peto Gehan-Wilcoxon test. The z-test of endpoints was used to compare 180-day survivals. Logistic regression was used to identify factors independently affecting 180-day survival. P values were two-tailed with corrections made for multiple comparisons by Bonferroni adjustment. One patient in group 1 failed to achieve remission and remaining patients engrafted. Median times to hematopoietic recovery were 11 days to neutrophils у0.5 ϫ 10 9 /l, ring before day 28 were also scored as grade 4. Adverse 12 days to neutrophils у1.0 ϫ 10 9 /l, 21 days to platelets events attributed to culture-documented infection, bleeding у20 ϫ 10 9 /l, and 27 days to platelets у50 ϫ 10 9 /l. or medications were not scored as RRT.
Results
Engraftment
Hematopoietic recovery differed between treatment groups. Hematopoietic recovery was significantly earlier for patients receiving CsA/MP as GVHD prophylaxis when Assessment of engraftment and GVHD compared to those receiving CsA/MTX (Table 2) . At the Neutrophil recovery was defined as the first of 3 consecutime of engraftment, the CsA/MP (groups 2 and 3) recipitive days with an absolute neutrophil count у0.5 ϫ 10 9 /l, ents had a rapid onset of neutrophilia that lasted several and platelet recovery was defined as the day the platelet days past the last dose of filgrastim (Figure 1 ). No patient count was у20 ϫ 10 9 /l with no platelet transfusions the developed graft rejection. Hematopoiesis was shown to be following week. Hematopoietic chimerism was evaluated donor in origin in all patients except for those with impendby conventional cytogenetics for sex-mismatched patienting (within 3 months) or active relapse. Platelet transfusions donor pairs and by DNA restriction fragment length polyexpressed as units per day survived to day 100 were sigmorphisms. 7 Diagnosis of GVHD was based on clinical and nificantly less for blood stem cell recipients than for marhistologic data. 8 GVHD was graded according to the conrow recipients receiving CsA/MP and similar to that for sensus criteria. 9 patients receiving CsA/MT (Table 2) .
Statistical considerations Regimen-related toxicity
Grade 2-4 RRT in at least one organ occurred in 72% of At the time of analysis, median time from transplantation was 24 months (range, 6-42 months) for all subjects.
patients, and grade 3-4 RRT in 12% of patients. Blood 
Acute graft-versus-host disease
Actuarial rate (95% CI) of grades 2-4 acute GVHD was 51% (38-63%), and grades 3-4 acute GVHD, 21% (11-32%). Grades 2-4 GVHD occurred in 49% (27-71%), 66% (42-91%) and 42% (22-63%) of groups 1, 2 and 3, respectively, and grades 3-4 GVHD occurred in 13% (0-28%), 33% (8-58%) and 22% (4-39%), respectively ( Figure 2 ). There were no significant differences between treatment groups. Steroid refractory acute GVHD occurred in 7% of group 1, 21% of group 2, and 20% of group 3 (P ϭ NS).
Outcome
Nineteen patients (26%) died prior to first discharge posttransplant; 67% of group 1, 74% of group 2, and 84% of group 3 patients were discharged (P ϭ NS). The median time to discharge was day 29 for group 1, day 19 for group 2, and day 15 for group 3 (P Ͻ 0.001 for group 1 vs group 3, and P ϭ 0.006 for group 2 vs group 3). Twenty-six patients died prior to day 100 with no significant differences between treatment groups (Table 4) . One hundred and eighty-day survival was 51% (95% CI, 40-63%) for all patients. Blood stem cell recipients had the best survival (Figure 3) . One hundred and eighty-day survival (95% CI) was 53% (35-72%) for group 1, 32% (10-53%) for group 2, and 68% (49-87%) for group 3. There was a significant survival advantage at 180 days for blood stem cell recipients only in comparison to bone marrow recipients receiving CsA/MP (P ϭ 0.02), and this difference remained significant in the logistic regression analysis adjusting for age Ͼ40 years, female donor, sex-mismatched donor, diagnosis, and response to reinduction pretransplant (P ϭ 0.04). The 2-year survival for all patients was 28% (95% CI, 15-40%). 
Discussion
In this study, we found that allogeneic blood stem cell stem cell recipients had the least RRT (Table 3) . Individual organ toxicities included stomatitis (53%), hepatotoxicity recipients had rapid hematopoietic recovery, a low incidence of toxicity, early discharge, and no increase in acute (28%), cardiac toxicity (9%), cystitis (8%), pulmonary toxicity (4%), nephrotoxicity (3%), gastrointestinal toxicity GVHD. Such results parallel the advantages of blood stem cell transplants over bone marrow transplants in the auto-(3%), and neurologic toxicity (1%). Blood stem cell recipients had significantly less grade 2-4 stomatitis (Table 3) , logous setting. [10] [11] [12] The salutory effects were associated with improvement in 180-day survival for blood stem cell but individual organ toxicity did not otherwise differ significantly between the three treatment groups.
recipients compared to bone marrow recipients receiving 459  Table 4 Causes of death prior to day 100 MTX. Neutrophil and platelet recoveries were slowest in the group receiving CsA/MTX for GVHD prophylaxis, and this References probably resulted from the myelosuppressive effects of MTX. Hematopoietic recoveries were essentially identical progenitors in blood stem cell grafts. (dashed line) and 3 (solid line). For group 1 vs 3, P ϭ NS; for group 2 vs 3, P ϭ 0.02.
